natgillin/translations-raw huggingface dataset:
Zoledronic Acid Hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronsko kislino vam sme dati samo zdravstveni delavec, ki je usposobljen za intravensko (kar pomeni v veno) dajanje difosfonatov.
Zoledronic Acid Hospira should be given as a single intravenous infusion in no less than 15 minutes.
Zdravilo Zoledronska kislina Hospira je treba dati v eni intravenski infuziji, ki ne traja manj kot 15 minut.
Zoledronic Acid Hospira treatment should be resumed at the same dose as that given prior to treatment interruption.
Zdravljenje z zoledronsko kislino je treba spet začeti z enakim odmerkom, kot ga je bolnik prejemal pred prekinitvijo zdravljenja.
Zoledronic Acid Hospira with food and drink
Zdravilo Zoledronska kislina Hospira skupaj s hrano in pijačo
Zoledronic Acid Hospira works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone.
Zdravilo Zoledronska kislina Hospira deluje tako, da normalizira proces kostne pregradnje, omogoči tvorbo normalne kostnine in tako kostem povrne čvrstost.
Zoledronic Acid Hospira, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zdravilo Zoledronska kislina Hospira, nadaljnje razredčeno v 100 ml (glejte poglavje 6.6), je treba dajati v obliki ene same intravenske infuzije, ki traja najmanj 15 minut.
Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and interactions resulting from displacement of highly protein-bound drugs are therefore unlikely.
Zoledronska kislina se ne veže v veliki meri na beljakovine v plazmi (vezana je približno v 43 - 55 %) zato interakcije, ki bi bile posledica izrinjanja zdravil, pretežno vezanih na beljakovine, niso verjetne.
Zoledronic acid is not recommended in women of childbearing potential.
Uporaba zoledronske kisline ni priporočena pri ženskah v rodni dobi.
Zoledronic acid medac
Zoledronska kislina medac
Zoledronic acid medac 4 mg/100 ml solution for infusion
Zoledronska kislina medac 4 mg/100 ml raztopina za infundiranje
Zoledronic acid medac 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Za bolnike z normalnim delovanjem ledvic je zdravilo Zoledronska kislina medac 4 mg/100 ml raztopina za infundiranje mogoče uporabiti takoj brez dodatne priprave.
Zoledronic acid medac 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zoledronska kislina medac 4 mg/100 ml raztopina za infundiranje vsebuje 4 mg zoledronske kisline v 100 ml infuzijske raztopine, ki je že pripravljena za uporabo pri bolnikih z normalno ledvično funkcijo.
Zoledronic acid medac 4 mg/100 ml solution for infusion Zoledronic acid
Zoledronska kislina medac 4 mg/100 ml raztopina za infundiranje zoledronska kislina
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion
Zoledronska kislina medac 4 mg/5 ml koncentrat za raztopino za infundiranje
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion
Zoledronska kislina medac 4 mg/5 ml koncentrat za raztopino za infundiranje zoledronska kislina
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronska kislina medac 4 mg/5 ml koncentrat za raztopino za infundiranje zoledronska kislina
Zoledronic acid medac 4mg/100ml solution for infusion
Zoledronska kislina medac 4 mg/100 ml raztopina za infundiranje
Zoledronic acid medac 4mg/5ml concentrate for solution for infusion
Zoledronska kislina medac 4 mg/5 ml koncentrat za raztopino za infundiranje
Zoledronic acid medac is supplied as a concentrate for solution for infusion in a 5 ml plastic vial made of clear, colourless plastic (cycloolefine copolymer) with rubber stopper (type I bromobutyl) and sealed with flip-off seal (aluminium and polypropylene).
Zdravilo Zoledronska kislina medac je v obliki koncentrata za raztopino za infundiranje v 5 ml plastični viali, narejeni iz prozorne, brezbarvne plastike (cikloolefinski kopolimer) z gumijastim zamaškom (tip 1 bromobutil), prevlečena z odtržno zaporko (aluminij ali polipropilen).
Zoledronic acid medac is supplied as packs containing 1 bottle or multipacks of 4 or 10 packs each containing 1 bottle.
Zdravilo Zoledronska kislina medac je na voljo v pakiranjih po eno steklenico ali skupno pakiranje po 4 ali 5 pakiranj s po 1 steklenico.
Zoledronic acid medac is supplied as packs containing 1 bottle or multipacks of 4 or 10 packs each containing 1 bottle.
Zdravilo Zoledronska kislina medac je na voljo v pakiranju z 1 škatlo ali skupnem pakiranju s 4 ali z 10 pakiranji, ki vsebujejo po 1 steklenico.
Zoledronic acid medac is supplied as solution for infusion in a 100 ml colourless glass bottle (type I) with rubber stoppers (halobutyl, fluoropolymer coated) and aluminium flip-off caps.
Zdravilo Zoledronska kislina medac je v obliki raztopine za infundiranje v 100 ml steklenice, narejeni iz brezbarvnega, prozornega stekla (tipa 1) z gumijastimi zamaški (halobutilna guma, prevlečena s fluoropolimerom) in z aluminijasto odtržno zaporko.
Zoledronic acid medac is supplied as unit packs containing 1 vial or 4 vials and as multipacks of 4 or 10 packs each containing 1 vial.
Zdravilo Zoledronska kislina medac je na voljo v posamičnih pakiranjih po 1 vialo ali 4 viale in v večodmernih pakiranjih s 4 ali 10 pakiranji, od katerih vsako vsebuje 1 vialo.
Zoledronic acid medac is supplied as unit packs containing 1 vial or 4 vials and as multipacks of 4 or 10 packs each containing 1 vial.
Zdravilo Zoledronska kislina medac je na voljo v posamičnih pakiranju, ki vsebuje 1 vialo ali 4 viale, ali v skupnem pakiranju s 4 ali z 10 pakiranji, ki vsebujejo po 1 vialo.
Zoledronic acid medac must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zdravila Zoledronska kislina medac se ne sme mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata, in jo je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
Zoledronic acid medac must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zdravilo Zoledronska kislina medac vam sme dati samo zdravstveni delavec, ki je usposobljen za intravensko (kar pomeni v veno) dajanje difosfonatov.
Zoledronic acid medac must only be prescribed and administered to patients by health care professionals experienced in the administration of intravenous bisphosphonates.
Zdravilo Zoledronska kislina medac smejo predpisovati in dajati bolnikom samo zdravstveni delavci, ki imajo izkušnje z uporabo intravenskih difosfonatov.
Zoledronic acid medac must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zdravilo Zoledronska kislina medac smejo predpisovati in dajati bolnikom samo zdravstveni delavci, ki imajo izkušnje z uporabo intravenskih difosfonatov.
Zoledronic acid must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronsko kislino vam sme dati samo zdravstveni delavec, ki je usposobljen za intravensko (kar pomeni v veno) dajanje difosfonatov.
Zoledronic acid Mylan
Zoledronska kislina Mylan
Zoledronic acid Mylan
Zolendronska kislina Mylan
Zoledronic acid Mylan 4 mg/5 ml concentrate for solution for infusion
Zoledronska kislina Mylan 4 mg/5 ml koncentrat za raztopino za infundiranje
Zoledronic acid Mylan 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zdravilo Zoledronska kislina Mylan 4 mg/5 ml koncentrat za raztopino za infundiranje, nadaljnje razredčeno v 100 ml (glejte poglavje 6.6), je treba dajati v obliki ene same intravenske infuzije, v času. ki ne sme biti krajši od 15 minut.
Zoledronic acid Mylan concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Koncentrata zdravila Zoledronska kislina Mylan se ne sme mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata in jo je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
Zoledronic acid Mylan concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Koncentrata Zoledronska kislina Mylan ne smete mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata, in jo je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
Zoledronic acid Mylan contains sodium
Zdravilo Zoledronska kislina Mylan vsebuje natrij.
Zoledronic acid Mylan is a clear and colourless concentrate for solution for infusion.
Zoledronska kislina Mylan je bister in brezbarven koncentrat za raztopino za infundiranje.
Zoledronic acid Mylan is a ‘generic medicine’.
Zdravilo Zoledronska kislina Mylan je generično zdravilo.
Zoledronic acid Mylan must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zdravilo Zoledronska kislina Mylan vam sme dati samo zdravstveni delavec, ki je usposobljen za intravensko (kar pomeni v veno) dajanje difosfonatov.
Zoledronic acid Mylan zoledronic acid
Zoledronska kislina Mylan zoledronska kislina
Zoledronic acid recommended dose*
Priporočeni odmerek zdravila zoledronske kisline
Zoledronic acid recommended dose*
Priporočeni odmerek zoledronske kisline
Zoledronic acid should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Pri sočasni uporabi zoledronske kisline z drugimi zdravili, ki lahko vplivajo na delovanje ledvic, je potrebna previdnost (glejte poglavje 4.5).
Zoledronic acid should only be resumed when serum creatinine returns to within 10 % of baseline.
Zdravljenje z zoledronsko kislino se sme spet začeti šele, ko se serumski kreatinin vrne na vrednost, ki ni za več kot 10 % večja od izhodiščne (glejte poglavje 4.2).
Zoledronic acid should only be resumed when serum creatinine returns to within 10% of baseline.
Zdravljenje z zdravilom Zoledronska kislina Mylan se sme spet začeti šele, ko se vrednost serumskega kreatinina zniža na vrednost, ki od izhodišne vrednosti ni višja od 10%.
Zoledronic acid shows no affinity for the cellular components of blood and plasma protein binding is low (approximately 56 %) and independent of the concentration of zoledronic acid.
Zoledronska kislina ne kaže nikakršne afinitete za celične sestavine krvi, vezava na plazemske beljakovine pa je majhna (okrog 56 %) in neodvisna od koncentracije zoledronske kisline.
Zoledronic acid shows no affinity for the cellular components of blood and plasma protein binding is low (approximately 56%) and independent of the concentration of zoledronic acid.
Zoledronska kislina ne kaže nikakršne afinitete za celične sestavine krvi, vezava na plazemske beljakovine pa je majhna (okrog 56 %) in neodvisna od koncentracije zoledronske kisline.
Zoledronic acid shows no appreciable binding to plasma proteins and does not inhibit human P450 enzymes in vitro (see section 5.2), but no formal clinical interaction studies have been performed.
Zoledronska kislina ne kaže znatne vezave na plazemske beljakovine in ne zavira humanih encimov P450 in vitro (glejte poglavje 5.2), niso pa bile izvedli formalnih kliničnih študij medsebojnega delovanja.
Zoledronic acid significantly decreased the incidence of one or more new vertebral fractures over three years and as early as the one year timepoint (see Table 2).
Zoledronska kislina je statistično značilno znižala incidenco enega ali več novih zlomov vretenc tako v obdobju treh let kot tudi že po enem letu opazovanja (glejte preglednico 2).
Zoledronic acid significantly reduced the mean days of limited activity by 17.9 days compared to placebo and significantly reduced the mean days of limited activity and the days of bed rest due to fractures by 2.9 days and 0.5 days respectively compared to placebo (all p<0.01).
Zoledronska kislina je v primerjavi s placebom statistično značilno znižala povprečno število dni z omejeno aktivnostjo za 17,9 dni v primerjavi s placebom in statistično značilno znižala povprečno število dni z omejeno aktivnostjo za 2,9 dni in število dni, v katerih je zaradi zlomov potreben počitek v postelji, za 0,5 dni (v vseh primerih p < 0,01).
Zoledronic acid Teva 4 mg/100 ml solution for infusion
Zoledronska kislina Teva 4 mg/100 ml raztopina za infundiranje
Zoledronic acid Teva 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Za bolnike z normalnim delovanjem ledvic je zdravilo Zoledronska kislina Teva 4 mg/100 ml raztopina za infundiranje mogoče uporabiti takoj brez dodatne priprave.
Zoledronic acid Teva 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zoledronska kislina Teva 4 mg/100 ml raztopina za infundiranje vsebuje 4 mg zoledronske kisline v 100 ml infuzijske raztopine, ki je že pripravljena za uporabo pri bolnikih z normalno ledvično funkcijo.
Zoledronic acid Teva 4 mg/100 ml solution for infusion must not be mixed with other infusion solutions and should be administered as a single intravenous solution in a separate infusion line.
Zdravila Zoledronska kislina Teva 4 mg/100 ml raztopina za infundiranje se ne sme mešati z drugimi infuzijskimi raztopinami in jo je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
Zoledronic acid Teva 4 mg/100 ml solution for infusion should be given as a single intravenous infusion in no less than 15 minutes.
Zdravilo Zoledronska kislina Teva 4 mg/100 ml raztopina za infundiranje je treba dajati v obliki ene same intravenske infuzije, ki traja najmanj 15 minut.
Zoledronic acid Teva 4 mg/100 ml solution for infusion Zoledronic acid
Zoledronska kislina Teva 4 mg/100 ml raztopina za infundiranje zoledronska kislina
Zoledronic Acid Teva 4 mg/5 ml concentrate for solution for infusion
Zoledronska kislina Teva 4 mg/5 ml koncentrat za raztopino za infundiranje
Zoledronic acid Teva 4mg/5ml concentrate for solution for infusion and Zoledronic acid teva 4mg/100ml solution for infusion
Zoledronska kislina Teva 4 mg/5 ml koncentrat za raztopino za infundiranje in Zoledronska kislina Teva 4 mg/100 ml raztopina za infundiranje
Zoledronic Acid Teva 4mg/5ml concentrate for solution for infusion only
Samo Zoledronska kislina Teva 4 mg/5 ml koncentrat za raztopino za infundiranje
Zoledronic Acid Teva concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Koncentrat zdravila Zoledronska kislina Teva se ne sme mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata in ga je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
Zoledronic acid Teva contains 15.6 mmol (or 359.6 mg) sodium per vial
Zdravilo Zoledronska kislina Teva vsebuje 15,6 mmol (ali 359,6 mg) natrija na vialo.
Zoledronic acid Teva Generics
Zoledronska kislina Teva Generics
Zoledronic acid Teva Generics 5 mg solution for infusion in bags
Zoledronska kislina Teva Generics 5 mg raztopina za infundiranje v vrečah
Zoledronic acid Teva Generics 5 mg solution for infusion in bottles
Zoledronska kislina Teva Generics 5 mg raztopina za infundiranje v plastenkah
Zoledronic acid Teva Generics 5 mg solution for infusion in bottles zoledronic acid
Zoledronska kislina Teva Generics 5 mg raztopina za infundiranje v plastenkah zoledronska kislina
Zoledronic acid Teva Generics 5 mg solution for infusion is ready for use.
Zdravilo Zoledronska kislina Teva Generics 5 mg raztopina za infundiranje v vialah je že pripravljena za uporabo.
Zoledronic acid Teva Generics 5 mg solution for infusion zoledronic acid
Zoledronska kislina Teva Generics 5 mg raztopina za infundiranje zoledronic acid
Zoledronic acid Teva Generics 5 mg solution for infusion zoledronic acid
Zoledronska kislina Teva Generics 5 mg raztopina za infundiranje zoledronska kislina
Zoledronic acid Teva Generics contains sodium
Zdravilo Zoledronska kislina Teva Generics vsebuje natrij
Zoledronic acid Teva Generics has no or negligible influence on the abililty to drive and use machines.
Zdravilo Zoledronska kislina Teva Generics nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Zoledronic acid Teva Generics has no or negligible influence on the ability to drive and use machines.
Zdravilo Zoledronska kislina Teva Generics nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Zoledronic acid Teva Generics is a clear and colourless solution for infusion.
Zdravilo Zoledronska kislina Teva Generics je bistra brezbarvna raztopina za infundiranje.
Zoledronic acid Teva Generics is a ‘generic medicine’.
Zdravilo Zoledronska kislina Teva Generics je „generično zdravilo“.
Zoledronic acid Teva Generics is also used to treat Paget’s disease of the bone in adults.
Zdravilo Zoledronska kislina Teva Generics se uporablja tudi za zdravljenje Pagetove bolezni kosti pri odraslih.
Zoledronic acid Teva Generics is not recommended for anyone under 18 years of age.
Uporaba zdravila Zoledronska kislina Teva Generics ni priporočljiva pri starosti pod 18 let.
Zoledronic acid Teva Generics may also cause other side effects
Zdravilo Zoledronska kislina Teva Generics lahko povzroča tudi druge neželene učinke
Zoledronic acid Teva Generics should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Pri sočasni uporabi zoledronske kisline z drugimi zdravili, ki lahko vplivajo na delovanje ledvic, je potrebna previdnost (glejte poglavje 4.5).
Zoledronic acid Teva Generics with food and drink
Zdravilo Zoledronska kislina Teva Generics skupaj s hrano in pijačo
Zoledronic acid Teva is a ‘generic medicine’.
Zdravilo Zoledronska kislina Teva je „generično zdravilo“.
Zoledronic acid Teva is contraindicated in breast-feeding women (see section 4.3).
Pri doječih materah je uporaba zdravila Zoledronska kislina Teva kontraindicirana (glejte poglavje 4.3).
Zoledronic Acid Teva is supplied as a concentrate for solution for infusion.
Zdravilo Zoledronska kislina Teva je koncentrat za raztopino za infundiranje.
Zoledronic acid Teva is supplied as a solution for infusion.
Zdravilo Zoledronska kislina Teva je na voljo v obliki raztopine za infundiranje.
Zoledronic acid Teva is supplied as packs containing 1, 4 or 10 bottles.
Zdravilo Zoledronska kislina Teva je na voljo v pakiranju po 1, 4 ali 10 plastenk.
Zoledronic acid Teva Pharma
Zoledronska kislina Teva Pharma
Zoledronic acid Teva Pharma (5 mg in 100 ml ready-to-infuse solution) is administered via a vented infusion line and given at a constant infusion rate.
Zdravilo Zoledronska kislina Teva Pharma (5 mg v 100 ml raztopine, pripravljene za infuzijo) se aplicira prek infuzijskega sistema s prezračevanjem in sicer s stalno hitrostjo infundiranja.
Zoledronic acid Teva Pharma 5 mg solution for infusion in bags
Zoledronska kislina Teva Pharma 5 mg raztopina za infundiranje v vrečah
Zoledronic acid Teva Pharma 5 mg solution for infusion in bags is ready for use.
Zdravilo Zoledronska kislina Teva Pharma 5 mg raztopina za infundiranje v vrečah je že pripravljena za uporabo.
Zoledronic acid Teva Pharma 5 mg solution for infusion in bags zoledronic acid
Zoledronska kislina Teva Pharma 5 mg raztopina za infundiranje v vrečah zoledronska kislina
Zoledronic acid Teva Pharma 5 mg solution for infusion in bottles
Zoledronska kislina Teva Pharma 5 mg raztopina za infundiranje v plastenkah
Zoledronic acid Teva Pharma 5 mg solution for infusion in bottles zoledronic acid
Zoledronska kislina Teva Pharma 5 mg raztopina za infundiranje v plastenkah zoledronska kislina
Zoledronic acid Teva Pharma 5 mg solution for infusion is ready for use.
Zdravilo Zoledronska kislina Teva Pharma 5 mg raztopina za infundiranje v vialah je že pripravljena za uporabo.
Zoledronic acid Teva Pharma 5 mg solution for infusion zoledronic acid
Zoledronska kislina Teva Pharma 5 mg raztopina za infundiranje zoledronic acid
Zoledronic acid Teva Pharma 5 mg solution for infusion zoledronic acid
Zoledronska kislina Teva Pharma 5 mg raztopina za infundiranje zoledronska kislina
Zoledronic acid Teva Pharma contains sodium
Zdravilo Zoledronska kislina Teva Pharma vsebuje natrij
Zoledronic acid Teva Pharma has no or negligible influence on the ability to drive and use machines.
Zdravilo Zoledronska kislina Teva Pharma nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Zoledronic acid Teva Pharma is a clear and colourless solution.
Zdravilo Zoledronska kislina Teva Pharma je bistra brezbarvna raztopina.
Zoledronic acid Teva Pharma is a ‘generic medicine’.
Zdravilo Zoledronska kislina kislina Teva Pharma je „generično zdravilo“.
Zoledronic acid Teva Pharma is not recommended in women of childbearing potential.
Za ženske, ki lahko zanosijo, Zoledronska kislina Teva Pharma ni priporočena.
Zoledronic acid Teva Pharma is supplied in multipacks containing 5 or 10 bags (5 bags of 100 ml or 10 bags of 100 ml).
Zoledronska kislina Teva Pharma je na voljo skupnem pakiranju po 5 ali 10 vreč (5 vreč po 100 ml ali 10 vreč po 100 ml).
Zoledronic acid Teva Pharma is supplied in packs of 1, 5 or 10 bottles.
Zoledronska kislina Teva Pharma je na voljo v pakiranjih po 1, 5 ali 10 plastenk.
Zoledronic acid Teva Pharma should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Pri sočasni uporabi zdravila Zoledronska kislina Teva Pharma z drugimi zdravili, ki lahko vplivajo na delovanje ledvic, je potrebna previdnost (glejte poglavje 4.5).
Zoledronic acid Teva Pharma with food and drink
Zdravilo Zoledronska kislina Teva Pharma s hrano in pijačo
Zoledronic acid Teva should only be resumed when serum creatinine returns to within 10% of baseline.
Zdravljenje z zdravilom Zoledronska kislina Teva se sme spet začeti šele, ko se serumski kreatinin vrne na vrednost, ki ni za več kot 10 % večja od izhodiščne.
Zoledronic acid treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Zdravljenje z zoledronsko kislino pri bolnikih s TIH, ki imajo tudi hudo ledvično okvaro, lahko pride v poštev šele po oceni razmerja med tveganji in koristmi zdravljenja.
Zoledronic acid treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Zdravljenje z zoledronsko kislinopri bolnikih s TIH, ki imajo tudi hudo ledvično okvaro, lahko pride v poštev šele po oceni razmerja med tveganji in koristmi zdravljenja.
Zoledronic acid treatment should be resumed at the same dose as that given prior to treatment interruption.
Zdravljenje z zdravilom Zoledronska kislina Mylan je treba ponovno začeti z enakim odmerkom kot ga je bolnik prejemal pred prekinitvijo zdravljenja.
Zoledronic acid treatment should be resumed at the same dose as that prior to treatment interruption.
Zdravljenje z zoledronsko kislino je treba spet začeti z enakim odmerkom kot ga je bolnik prejemal pred prekinitvijo zdravljenja.